Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
Lebwohl
M
M
Department of Dermatology, Mount Sinai Medical Center, New York, New York, USA.
Lombardi
K
K
Tan
M H
MH
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005782:Gels; D005938:Glucocorticoids; D006801:Humans; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D012176:Retinoids
D000893:Anti-Inflammatory Agents; D002990:Clobetasol; D003879:Dermatologic Agents; D005782:Gels; D005938:Glucocorticoids; D009539:Nicotinic Acids; D009824:Ointments; C086827:tazarotene; D012176:Retinoids